Under the terms of the deal Akorn will be responsible for the manufacture and supply of the product. Akorn is the abbreviated new drug application (ANDA) holder and will begin supplying thr product in the first half of 2009.
Arthur Przybyl, Akorn's CEO, said: "The completion of this agreement represents the fifth new ophthalmic partnership in 2008 for our contract manufacturing business. We continue to seek opportunities in ophthalmics, liquid and lyophilized injectable products in order to expand our contract pharmaceutical business segment revenues."